Novo Nordisk Expands Obesity Drug to Children, But Market Hesitates on Adoption

A landmark semaglutide trial showed the GLP-1 treatment can reduce obesity in children as young as six to below the obesity threshold. Markets showed little immediate reaction, while reimbursement, prescribing rules, and broader social acceptance remain key uncertainties for pediatric adoption and the drug's commercial potential.